The Position of Combination Chemotherapy with Mitomycin C and Methotrexate in the Treatment of Metastatic Breast Cancer - Especially Triple Negative Breast Cancer

Tanabe, Masahiko; Fukuda, Takayo; Ito, Yoshinori

doi:10.7150/oncm.21071

Full Text | PDF

Oncomedicine 2017; 2:126-131. doi:10.7150/oncm.21071 This volume Cite

Review

The Position of Combination Chemotherapy with Mitomycin C and Methotrexate in the Treatment of Metastatic Breast Cancer - Especially Triple Negative Breast Cancer

Masahiko Tanabe^1✉, Takayo Fukuda², Yoshinori Ito²

1. Kyoundo Hospital, Department of Breast Surgical Oncology, 1-8, Kanda-Surugadai Chiyoda-ku, Tokyo, 101-0062, Japan
2. The Cancer Institute Hospital of JFCR (Japanese Foundation for Cancer Research), Department of Breast Medical Oncology, 3-8-31, Ariake, Koto-ku, Tokyo, 135-8550, Japan

Citation:

Tanabe M, Fukuda T, Ito Y. The Position of Combination Chemotherapy with Mitomycin C and Methotrexate in the Treatment of Metastatic Breast Cancer - Especially Triple Negative Breast Cancer. Oncomedicine 2017; 2:126-131. doi:10.7150/oncm.21071. http://www.oncm.org/v02p0126.htm

Other styles

Abstract

Complete cure of metastatic breast cancer (MBC) remains difficult, despite the development of new drugs. Triple negative (TN) breast cancer, which is defined by lack of hormone receptor (estrogen and progesterone receptors) expressions and the absence of human epidermal growth factor receptor type 2 (HER2) overexpression, is especially associated with poor long-term outcomes as compared with other breast cancer subtypes. Therefore, many patients with TN-MBC eagerly await promising novel treatments for TN-MBC. While new drugs are being developed, several conventional drugs such as mitomycin C (MMC) and methotrexate (MTX) are being used less. We reviewed our previous reports on combination chemotherapy with MMC and MTX (MMC/MTX) after multiple treatments. For the MMC/MTX regimen, MMC 8 mg/m²on day 1 and MTX 60mg/m² on days 1 and 15 were administered intravenously every 4 weeks. MMC/MTX was effective for 24% of 48 MBC patients who had been treated with anthracycline and taxane, resulting in a median time to progression (TTP) of 4.8 months. In addition, MMC/MTX was effective for 9.7 - 19.4 % of 31 patients with HER2-negative MBC after multiple treatments with anthracycline, taxane, capecitabine and vinorelbine, resulting in a median TTP of 3.9 months. Among 10 patients with TN-MBC, a partial response was observed in two (20%) and stable disease in three (30%). Thus, MMC/MTX controlled TN-MBC relatively well. Among TN-MBC patients maintaining good performance status without myelosuppression, MMC/MTX might be an option for those in whom no other treatments are effective after multiple regimens suggested in the guidelines.

Keywords: metastatic breast cancer, triple negative breast cancer, combination chemotherapy with MMC and MTX

Citation styles

APA

Tanabe, M., Fukuda, T., Ito, Y. (2017). The Position of Combination Chemotherapy with Mitomycin C and Methotrexate in the Treatment of Metastatic Breast Cancer - Especially Triple Negative Breast Cancer. Oncomedicine, 2, 126-131. https://doi.org/10.7150/oncm.21071.

ACS

Tanabe, M.; Fukuda, T.; Ito, Y. The Position of Combination Chemotherapy with Mitomycin C and Methotrexate in the Treatment of Metastatic Breast Cancer - Especially Triple Negative Breast Cancer. Oncomedicine 2017, 2, 126-131. DOI: 10.7150/oncm.21071.

NLM

CSE

Tanabe M, Fukuda T, Ito Y. 2017. The Position of Combination Chemotherapy with Mitomycin C and Methotrexate in the Treatment of Metastatic Breast Cancer - Especially Triple Negative Breast Cancer. Oncomedicine. 2:126-131.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.